{
    "data": [
        {
            "title": "How Investors May Respond To Sunrun (RUN) Profit Swing and Surging Home Storage Adoption",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Sunrun Inc. has reported its fourth-quarter and full-year 2025 results, with sales reaching US$466.49¬†million for the quarter and US$1.82¬†billion for the year, revenue of US$1.16¬†billion for the quarter and US$2.96¬†billion for the year, and a swing from a multi‚Äëbillion‚Äëdollar net loss in 2024 to net income of US$103.57¬†million for the quarter and US$449.95¬†million for 2025.</li> <li>Beyond the earnings beat, Sunrun‚Äôs growing battery footprint, now more than 217,000 residential systems and a 71% storage attachment rate, underpins its expanding role in grid services, highlighted by a successful distributed power plant season with PG&amp;E that achieved nearly 99% dispatch accuracy across over 1,200 hours.</li> <li>We‚Äôll now examine how Sunrun‚Äôs sharp turnaround to profitability and rising storage attachment rates might reshape its existing investment narrative.</li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Sunrun Investment Narrative Recap</h2><p>To own Sunrun, you need to believe residential solar plus storage can remain attractive even as tax credits phase out and financing stays complex. The latest earnings beat and return to profitability strengthen the case that scale and higher storage attachment can support margins, but the biggest near term swing factor is still access to affordable capital, while long term policy uncertainty around incentives remains a key overhang. This quarter‚Äôs results do not remove those risks, but they do improve Sunrun‚Äôs financial footing.</p> <p>The most relevant recent development is Sunrun‚Äôs completion of the PG&amp;E Local PeakShift Power season, where over 1,000 customer systems delivered nearly 1,200 hours of highly accurate dispatch. Paired with storage attachment rates reaching 71% by year end 2025, this grid services performance gives more substance to the idea that batteries and virtual power plants could become a meaningful earnings driver, potentially offsetting some pressure from expiring tax credits and higher financing costs over time.</p> <p>Yet while the profit rebound is encouraging, investors should also be aware that concentrated policy risk around solar tax credits could still...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-run/sunrun/puusfyum-run-supportive-policy-changes-and-market-demand-will-drive-mixed-outcomes-ahead\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Sunrun (it's free!)</a></p><p>Sunrun's narrative projects $2.9 billion revenue and $465.4 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-run/sunrun/puusfyum-run-supportive-policy-changes-and-market-demand-will-drive-mixed-outcomes-ahead\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Sunrun's forecasts yield a $22.74 fair value</a>, a 11% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"RUN 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/9fa2a4c7-de78-47ca-906e-c5edae8a6116/chart/quote-price\" width=\"746\"/></a><figcaption>RUN 1-Year Stock Price Chart</figcaption></figure> <p>Before this surprise profit, the most bearish analysts assumed almost flat revenue growth near US$2.1 billion and no profitability, so their far more cautious view of Sunrun‚Äôs financing and policy risks may shift meaningfully as investors reassess those assumptions.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 5 other fair value estimates on Sunrun</a> - why the stock might be worth as much as 32% more than the current price!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Sunrun research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Sunrun research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sunrun's overall financial health at a glance.</li></ul><h2>No Opportunity In Sunrun?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</li><li>Explore <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 top quantum computing companies</a> leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:40:58",
            "link": "https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun/news/how-investors-may-respond-to-sunrun-run-profit-swing-and-sur",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following New 2026 Revenue Guidance Release",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Amneal Pharmaceuticals recently issued 2026 earnings guidance, projecting net revenue between US$3.05¬†billion and US$3.15¬†billion, alongside heightened attention around its latest quarterly earnings release.</li> <li>This new guidance gives investors a clearer view of management‚Äôs expectations for the scale of Amneal‚Äôs business as it expands across generics, injectables, biosimilars, and specialty products.</li> <li>We‚Äôll now examine how Amneal‚Äôs US$3.05‚Äì3.15¬†billion 2026 revenue outlook may influence the existing investment narrative built around diversification.</li> </ul><p>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Amneal Pharmaceuticals Investment Narrative Recap</h2><p>To own Amneal, you need to believe its push across generics, injectables, biosimilars, and specialty products can offset pricing pressure and legal costs while supporting sustainable scale. The new 2026 revenue guidance of US$3.05‚Äì3.15 billion reinforces that diversification story but does not materially change the near term focus on execution in higher margin categories or the key risk around ongoing pricing and regulatory pressures.</p> <p>The most relevant recent announcement here is the nationwide opioids settlement, which commits Amneal to up to US$88.5 million in cash payments and up to US$177.4 million in naloxone product. That settlement helps clarify a major legal overhang just as management is asking investors to weigh its revenue outlook and pipeline against elevated leverage and the cost of maintaining compliance and quality across a broad portfolio.</p> <p>Yet behind this clearer revenue outlook and legal visibility, investors should still be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/3tt90axt-amrx-recent-fda-approvals-and-pipeline-launches-will-drive-upside-momentum\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Amneal Pharmaceuticals (it's free!)</a></p><p>Amneal Pharmaceuticals‚Äô narrative projects $3.5 billion revenue and $207.9 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/3tt90axt-amrx-recent-fda-approvals-and-pipeline-launches-will-drive-upside-momentum\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Amneal Pharmaceuticals' forecasts yield a $15.20 fair value</a>, a 5% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"AMRX 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/quote-price\" width=\"746\"/></a><figcaption>AMRX 1-Year Stock Price Chart</figcaption></figure> <p>Three fair value estimates from the Simply Wall St Community span roughly US$11.94 to about US$70 per share, showing how far apart individual views on Amneal‚Äôs potential can be. Against that backdrop, Amneal‚Äôs new 2026 revenue guidance invites you to weigh its diversification catalyst alongside ongoing pricing and regulatory risks that could influence how those projections translate into business performance.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Amneal Pharmaceuticals</a> - why the stock might be worth over 4x more than the current price!</p><h2>Form Your Own Verdict</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Amneal Pharmaceuticals research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Amneal Pharmaceuticals research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amneal Pharmaceuticals' overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li><li>The latest GPUs need a type of rare earth metal called Dysprosium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>This technology could replace computers: discover <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 stocks that are working to make quantum computing a reality</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:40:58",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/news/the-bull-case-for-amneal-pharmaceuticals-amrx-could-change-f-3",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is National Energy Services Reunited (NESR) Share Surge Justified By Recent Valuation Signals",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>This article is designed to help you assess whether National Energy Services Reunited still represents good value after its recent share price run, or whether the excitement has moved ahead of the company‚Äôs fundamentals.</li> <li>The stock last closed at US$25.14, with returns of 3.9% over 7 days, 26.0% over 30 days, 59.2% year to date and 207.7% over the past year, as well as 278.6% over 3 years and 95.0% over 5 years.</li> <li>These moves have put the company on more investors' radar, and they have been looking more closely at how its current price lines up with its underlying worth. That is where a structured valuation review comes in, using multiple methods to see whether the recent share price action still matches the fundamentals.</li> <li>On our Simply Wall St checks, National Energy Services Reunited scores 2 out of 6 on valuation, which you can see in detail in our <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">valuation scorecard</a>. Next we will walk through the different ways investors commonly assess value, before finishing with a more complete way to think about valuation as a whole.</li> </ul> <p>National Energy Services Reunited scores just 2/6 on our valuation checks. See what other red flags we found in the <a class=\"company-report-links\" data-vars-link-type=\"cta_low_value_score\" href=\"https://www.simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">full valuation breakdown</a>.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Approach 1: National Energy Services Reunited Discounted Cash Flow (DCF) Analysis</h2> <p>A Discounted Cash Flow, or DCF, model takes the cash that a company is expected to generate in the future and discounts it back to today to estimate what the entire business could be worth now.</p> <p>For National Energy Services Reunited, the latest twelve month Free Cash Flow is about $153.0 million. The model used here is a 2 Stage Free Cash Flow to Equity approach, which first applies analyst forecasts and then extends those cash flows further out using additional assumptions by Simply Wall St.</p> <p>The projections used in the model include Free Cash Flow of $154.6 million in 2026 and $219.0 million in 2028, with further years out to 2035 based on extrapolated estimates, all in $. When these projected cash flows are discounted back to today, the DCF model arrives at an estimated intrinsic value of about $58.38 per share.</p> <p>Compared with the recent share price of $25.14, this DCF estimate suggests a difference of around 56.9% between the modelled intrinsic value and the current market price.</p> <p><strong>Result: UNDERVALUED (based on this DCF model)</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests National Energy Services Reunited is undervalued by 56.9%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NESR Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7f4533ec-72e9-4bee-b095-b8fa053aca99/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>NESR Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for National Energy Services Reunited.</a></p> <h2>Approach 2: National Energy Services Reunited Price vs Earnings</h2> <p>For a profitable company, the P/E ratio is a straightforward way to see how much you are paying for each dollar of earnings. This makes it a useful cross check alongside a DCF model. What counts as a ‚Äúnormal‚Äù P/E depends on what the market expects for future earnings growth and how risky those earnings are, with higher expected growth or lower perceived risk usually supporting a higher multiple.</p> <p>National Energy Services Reunited currently trades on a P/E of about 49.6x. That sits above both the Energy Services industry average of roughly 26.6x and the peer group average of about 32.7x. This suggests the market is applying a richer multiple than these broad comparison points.</p> <p>Simply Wall St‚Äôs Fair Ratio for the stock is 25.9x. This is a proprietary estimate of what the P/E might be based on factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it ties the multiple to these fundamentals, the Fair Ratio can offer a more tailored reference point than a simple peer or industry comparison.</p> <p>When set against the current P/E of 49.6x, the Fair Ratio of 25.9x points to the shares trading on a higher multiple than this framework would suggest.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqCM:NESR P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7f4533ec-72e9-4bee-b095-b8fa053aca99/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqCM:NESR P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your National Energy Services Reunited Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you set out your story for National Energy Services Reunited, link that story to a forecast for revenue, earnings and margins, and then see the Fair Value that falls out of those assumptions so you can compare it with the current share price.</p> <p>Instead of only relying on a single P/E or DCF number, a Narrative combines your view of the business with a live model. It updates automatically when new earnings or news arrive, and is available on the Community page where millions of investors share their own versions.</p> <p>For example, one National Energy Services Reunited Narrative might align with the bullish analyst fair value of US$30.00, built around confidence in hydraulic fracturing capacity and MENA contracts. Another could sit nearer the cautious US$10.00 view that focuses on regional concentration and energy transition risks. Seeing those side by side can help you decide whether the current US$25.14 price is above or below the story you find most convincing.</p> <p>For National Energy Services Reunited, here are previews of two leading National Energy Services Reunited narratives that may help frame the discussion:</p> <p><a href=\"/us/energy/nasdaq-nesr/national-energy-services-reunited/lj4o0x5w-rising-mena-demand-will-boost-oilfield-service-expansion-mfij?utm_medium=finance_user&amp;utm_campaign=cta_bull_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêÇ National Energy Services Reunited Bull Case</strong></a></p> <p>Fair value in this bullish narrative: US$30.00 per share</p> <p>Current price vs this fair value: about 16.1% below the narrative fair value</p> <p>Assumed revenue growth used in this narrative: 19.65% a year</p> <ul> <li>Supports a higher fair value case built around hydraulic fracturing scale in Saudi Arabia, contract visibility across MENA and higher profit margins tied to technology and efficiency gains.</li> <li>Assumes National Energy Services Reunited can sustain robust revenue growth and margin expansion, with future earnings and P/E considered consistent with a US$30.00 anchor valuation.</li> <li>Notes meaningful risks from oilfield concentration, regional exposure and capital intensity, so the optimistic outcome still depends on execution and stable operating conditions.</li> </ul> <p><a href=\"/us/energy/nasdaq-nesr/national-energy-services-reunited/1sh65zqm-revenue-recovery-and-sector-rebound-will-drive-long-term-shareholder-returns?utm_medium=finance_user&amp;utm_campaign=cta_bear_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêª National Energy Services Reunited Bear Case</strong></a></p> <p>Fair value in this more cautious narrative: US$22.14 per share</p> <p>Current price vs this fair value: about 13.5% above the narrative fair value</p> <p>Assumed revenue growth used in this narrative: 18.93% a year</p> <ul> <li>Frames the story around solid MENA contracts and Jafurah exposure, but anchors fair value closer to US$22.14, even with updated analyst targets around US$30.</li> <li>Builds in steady revenue growth and margin improvement, while assuming a more modest future P/E multiple compared with the bullish view.</li> <li>Highlights contract concentration, capital demands, working capital strain and long term energy transition as key risks that could keep the share price nearer this fair value.</li> </ul> <p>Viewed together, these narratives provide two different sets of assumptions for National Energy Services Reunited that can be compared with the current US$25.14 share price.</p> <p>Do you think there's more to the story for National Energy Services Reunited? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqCM/NESR\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/energy/nasdaq-nesr/national-energy-services-reunited\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqCM:NESR 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7f4533ec-72e9-4bee-b095-b8fa053aca99/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqCM:NESR 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if National Energy Services Reunited might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 00:40:57",
            "link": "https://simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/news/is-national-energy-services-reunited-nesr-share-surge-justif",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Why Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Detailed Ryoncil Revenue Guidance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Mesoblast Limited recently reported half-year 2025 results, with revenue rising to US$51.34 million and net loss and loss per share both narrowing, and subsequently issued fiscal 2026 guidance calling for US$110 million to US$120 million in Ryoncil net revenue.</li> <li>This combination of sharply higher reported revenue and the first detailed full-year outlook for Ryoncil offers investors a clearer view of Mesoblast‚Äôs early commercial trajectory and cost profile.</li> <li>We‚Äôll now examine how Mesoblast‚Äôs new Ryoncil revenue guidance reframes its investment narrative built around cell therapy commercialization and pipeline expansion.</li> </ul><p>Rare earth metals are the new gold rush. Find out which <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 stocks are leading the charge</a>.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Mesoblast Investment Narrative Recap</h2><p>To own Mesoblast today, you need to believe that Ryoncil can scale from a niche pediatric GvHD launch into a broader cell therapy franchise while the company manages ongoing losses and funding needs. The sharp step up in reported revenue and the new US$110 million to US$120 million Ryoncil guidance sharpen the focus on near term execution: can demand ramp fast enough to ease cash burn, and will trial and regulatory timelines hold without costly delays?</p> <p>The half year 2025 results are the most relevant recent announcement here, because they show early financial traction alongside continuing losses. Revenue of US$51.34 million and a reduced but still sizeable net loss of US$40.16 million underscore the tension between growing top line and the risk that R&amp;D and commercial spend remain high if label expansions in adult GvHD, inflammatory bowel disease or chronic low back pain take longer than expected to translate into meaningful sales.</p> <p>Yet against this improving revenue picture, the risk that slower Ryoncil uptake or trial delays could still force fresh capital raises is something investors should be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/tz4l8krr-update-for-mesoblast\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Mesoblast (it's free!)</a></p><p>Mesoblast's narrative projects $485.4 million revenue and $222.1 million earnings by 2029. This requires 204.5% yearly revenue growth and a $324.2 million earnings increase from -$102.1 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/tz4l8krr-update-for-mesoblast\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Mesoblast's forecasts yield a A$3.83 fair value</a>, a 71% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ASX:MSB 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/600844ad-7b8f-4b60-be67-41aeee6634b3/chart/quote-price\" width=\"746\"/></a><figcaption>ASX:MSB 1-Year Stock Price Chart</figcaption></figure> <p>The more optimistic analysts were already assuming revenue could reach about US$1.1 billion and earnings about US$585 million by 2028, so compared with the more cautious concerns about cash burn and trial risk, their narrative is far more bullish and you should recognize that views on Mesoblast can differ widely and may shift again after this new Ryoncil guidance.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 17 other fair value estimates on Mesoblast</a> - why the stock might be a potential multi-bagger!</p><h2>The Verdict Is Yours</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Mesoblast research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Mesoblast research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mesoblast's overall financial health at a glance.</li></ul><h2>Interested In Other Possibilities?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/au\" rel=\"noopener noreferrer\" target=\"_blank\">10 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:40:57",
            "link": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-down-71-after-issuing-first-detailed",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Why ServiceTitan (TTAN) Is Up 10.5% After Morgan Stanley Names It A Sector Top Pick",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In recent weeks, ServiceTitan was highlighted by Wall Street analysts as one of the best beaten down technology names, with Morgan Stanley upgrading it to Overweight and naming it a sector top pick while institutional investors such as Artisan increased their holdings following earlier software weakness.</li> <li>These moves underscore growing institutional and analyst confidence in ServiceTitan‚Äôs vertical software model for trades and its potential to expand across additional end markets and product lines.</li> <li>We‚Äôll now examine how this renewed analyst and institutional confidence, especially Morgan Stanley‚Äôs sector top pick call, could influence ServiceTitan‚Äôs investment narrative.</li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>ServiceTitan Investment Narrative Recap</h2><p>To own ServiceTitan, you have to believe its vertical software can keep becoming the core system of record for trades while its AI, payments and MAX initiatives deepen customer reliance on the platform. The recent analyst upgrade and institutional buying may support sentiment around the near term catalyst of broader MAX and AI Pro adoption, but they do not remove the key risk that these agentic, automated workflows could prove harder for customers to implement at scale.</p> <p>Among recent announcements, the expansion of ServiceTitan‚Äôs AP Automation and fintech suite, including Tap to Pay and integrated financing, ties in most closely with the current bull thesis around usage based payments and higher take rates. If these tools see sustained customer adoption, they could reinforce the catalysts tied to payments and workflow automation that analysts are watching, even as questions about implementation complexity and returns on AI investments remain in focus.</p> <p>Yet behind the renewed optimism, investors should also be aware that the long term bet on AI driven automation and the MAX program could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/software/nasdaq-ttan/servicetitan/7pmj2q50-update-for-servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on ServiceTitan (it's free!)</a></p><p>ServiceTitan's narrative projects $1.5 billion revenue and $188.8 million earnings by 2028. This requires 18.4% yearly revenue growth and about a $486.9 million earnings increase from -$298.1 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/software/nasdaq-ttan/servicetitan/7pmj2q50-update-for-servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how ServiceTitan's forecasts yield a $136.33 fair value</a>, a 85% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TTAN 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/254bf5df-024c-4f4c-b03f-feca2d584ec2/chart/quote-price\" width=\"746\"/></a><figcaption>TTAN 1-Year Stock Price Chart</figcaption></figure> <p>Five fair value estimates from the Simply Wall St Community span roughly US$38 to US$136 per share, showing how differently holders view ServiceTitan‚Äôs potential. Against that wide spread, the core debate around whether AI driven automation and MAX can deliver clear, scalable customer ROI becomes a key lens for thinking about the company‚Äôs longer term performance and invites you to compare several alternative viewpoints.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 5 other fair value estimates on ServiceTitan</a> - why the stock might be worth 48% less than the current price!</p><h2>Decide For Yourself</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your ServiceTitan research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Our free ServiceTitan research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ServiceTitan's overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>The latest GPUs need a type of rare earth metal called Dysprosium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:40:57",
            "link": "https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan/news/why-servicetitan-ttan-is-up-105-after-morgan-stanley-names-i",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Should Rising Analyst Optimism Around Earnings Shift On Holding‚Äôs (ONON) Long‚ÄëTerm Growth Narrative?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In recent days, On Holding attracted heightened attention as UBS and Zacks reiterated very positive views ahead of the company‚Äôs now-past 3 March 2026 earnings release, citing strong consumer momentum, solid revenue growth and earlier earnings surprises. </li> <li>This cluster of upbeat analyst commentary has sharpened focus on how On‚Äôs recent operational performance may be reshaping expectations for its long-term growth profile and profitability. </li> <li>Now, we‚Äôll examine how this rising analyst optimism around operational strength and upcoming results could influence On Holding‚Äôs existing investment narrative. </li> </ul><p>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>On Holding Investment Narrative Recap</h2><p>To own On Holding, you need to believe its premium brand, product innovation and DTC focus can justify a high valuation and support durable growth. The immediate catalyst is the 3 March 2026 Q4 2025 earnings release, which sits at the center of the recent analyst optimism. The biggest near term risk is that expectations for continued revenue and earnings momentum are now elevated, so any disappointment could magnify share price volatility.</p> <p>The most relevant recent announcement is On‚Äôs 10 February 2026 confirmation of its Q4 2025 earnings date. With analysts already highlighting prior earnings surprises and solid revenue growth, this specific release has become a focal point for testing the bullish thesis on margins, DTC progress and international scaling. How the company‚Äôs reported sales and profitability compare with these expectations may either reinforce, or start to question, the current enthusiasm embedded in the shares.</p> <p>Yet beneath the upbeat commentary, the risk that heavy reliance on premium pricing could eventually face pushback is something investors should be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nyse-onon/on-holding/pr8lhrz5-analyst-commentary-reveals-mixed-views-as-on-holding-adjusts-guidance-and-targets\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on On Holding (it's free!)</a></p><p>On Holding‚Äôs narrative projects CHF5.0 billion revenue and CHF561.2 million earnings by 2028. This requires 22.9% yearly revenue growth and an earnings increase of about CHF425 million from CHF135.9 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nyse-onon/on-holding/pr8lhrz5-analyst-commentary-reveals-mixed-views-as-on-holding-adjusts-guidance-and-targets\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how On Holding's forecasts yield a $61.90 fair value</a>, a 30% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ONON 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/30b460e6-f1a8-445d-9f78-310d4e375cd1/chart/quote-price\" width=\"746\"/></a><figcaption>ONON 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts were assuming revenue could climb toward CHF 5.5 billion and earnings to about CHF 725 million by 2028, which is far more upbeat than consensus and could be challenged if the recent focus on Asia Pacific expansion leaves results more exposed to regional slowdowns or shocks.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 16 other fair value estimates on On Holding</a> - why the stock might be worth just $45.33!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your On Holding research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\">Our free On Holding research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate On Holding's overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 best rare earth metal stocks</a> of the very few that mine this essential strategic resource.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 00:35:55",
            "link": "https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding/news/should-rising-analyst-optimism-around-earnings-shift-on-hold",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "SentinelOne Unveils Identity Platform As Market Weighs Losses And Valuation",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>SentinelOne (NYSE:S) has launched a next generation identity security platform focused on protecting both human users and AI agent accounts.</li> <li>The new offering shifts from traditional authentication checks to continuous, behavior based validation and runtime authorization withdrawal.</li> <li>The move targets rising identity centric threats as enterprises adopt more automation and AI driven workflows.</li> </ul> <p>SentinelOne enters this launch with shares at $13.48 and a mixed recent track record, including a 10.8% decline over the past 30 days and a 33.7% decline over the past year. For investors following NYSE:S, the new platform reflects how the company is trying to position itself in identity security as attack surfaces evolve.</p> <p>For investors and customers, the key question is how much demand develops for identity protection that explicitly includes AI agents alongside human users. This release also indicates where SentinelOne is focusing its product roadmap, which may influence how its role within broader cybersecurity exposure in a portfolio is evaluated.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">SentinelOne</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/S\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on SentinelOne.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:S Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/f2abf38f-6e34-40bd-a59e-9d368e694ec3/chart/earnings-and-revenue-growth?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:S Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 2 risks for SentinelOne. See which could impact your investment.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚úÖ Price vs Analyst Target</strong>: At $13.48 versus an average analyst target of $20.71, the price sits about 35% below consensus expectations.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: Shares are described as trading 44.4% below an estimated fair value, which flags potential upside based on that model.</li> <li><strong>‚ùå Recent Momentum</strong>: The stock has a 30 day return of about 10.8% decline, so the market has been cautious recently.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold SentinelOne: head to Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of SentinelOne's Fair Value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä The new identity platform extends SentinelOne's reach into protecting both human and AI agent accounts, which could broaden its role in zero trust and automation heavy environments.</li> <li>üìä Keep an eye on customer adoption, any commentary on AI related deal wins, and whether revenue of US$955.65m starts to reflect traction from this product line.</li> <li>‚ö†Ô∏è The company is currently loss making with net income of a US$411.29m loss and is flagged as not forecast to reach profitability within 3 years, so funding and cash burn remain key watchpoints.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture including more risks and rewards, check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone\" rel=\"noopener noreferrer\" target=\"_blank\">complete SentinelOne analysis</a>. Alternatively, you can visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/S\" rel=\"noopener noreferrer\" target=\"_blank\">community page for SentinelOne</a> to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:35:55",
            "link": "https://simplywall.st/stocks/us/software/nyse-s/sentinelone/news/sentinelone-unveils-identity-platform-as-market-weighs-losse",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Earnings Beat And New Audit Voice Altering The Investment Case For Darling Ingredients (DAR)?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Darling Ingredients recently reported quarterly revenues that came in well above analyst expectations, with management highlighting strong operational execution, EBITDA growth and improved gross margins despite industry headwinds.</li> <li>The company also disclosed a planned 2026 retirement of long-time lead director Gary Mize and the immediate addition of former Cargill executive Robert Aspell to the board and Audit Committee, potentially sharpening oversight around global agriculture exposure and risk management.</li> <li>Against this backdrop of earnings outperformance and fresh audit expertise from Robert Aspell, we‚Äôll assess how Darling Ingredients‚Äô investment narrative may evolve.</li> </ul><p>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Darling Ingredients Investment Narrative Recap</h2><p>To own Darling Ingredients, you need to believe its mix of rendering, renewable fuels and specialty ingredients can translate volatile inputs and policy swings into steadier cash generation. The latest revenue beat and margin improvement support that thesis, but do not materially change the near term focus on renewable fuel policy clarity as the key catalyst, or on weak recent profitability and high leverage as central risks.</p> <p>The most relevant development for that near term story is the board change. Adding former Cargill executive Robert Aspell, with deep global agriculture and risk experience, to the Audit Committee could sharpen oversight around feedstock exposure, capital allocation and compliance just as Darling works through margin volatility and balance sheet constraints in its Fuel and Feed segments.</p> <p>Yet against the recent earnings volatility and tight interest coverage, one area investors should be especially aware of is the risk that prolonged regulatory uncertainty could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/food-beverage-tobacco/nyse-dar/darling-ingredients/m6tj1w9q-us-renewable-mandates-and-specialty-ingredients-will-power-market-evolution-ybid\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Darling Ingredients (it's free!)</a></p><p>Darling Ingredients' narrative projects $6.5 billion revenue and $673.1 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/food-beverage-tobacco/nyse-dar/darling-ingredients/m6tj1w9q-us-renewable-mandates-and-specialty-ingredients-will-power-market-evolution-ybid\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Darling Ingredients' forecasts yield a $47.46 fair value</a>, a 10% downside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"DAR 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/ddd8b6e1-179a-4580-91d0-0fba71c1152c/chart/quote-price\" width=\"746\"/></a><figcaption>DAR 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts expect revenue near US$6.8 billion and earnings around US$891.1 million by 2028, whereas concerns about rising capex and regulatory dependence paint a much tougher picture, and this quarter‚Äôs earnings beat and governance changes could ultimately shift how you weigh those competing views.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Darling Ingredients</a> - why the stock might be worth 10% less than the current price!</p><h2>The Verdict Is Yours</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Darling Ingredients research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 4 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Darling Ingredients research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Darling Ingredients' overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Our daily scans reveal stocks with breakout potential. Don't miss this chance:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:35:55",
            "link": "https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients/news/is-earnings-beat-and-new-audit-voice-altering-the-investment",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Lithia Motors (LAD) Valuation After Recent Share Price Pullback",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Why Lithia Motors stock is drawing attention now</h2> <p>Lithia Motors (LAD) has been on many investors‚Äô radar after recent share performance, with the stock showing a negative move over the month and past 3 months, prompting closer scrutiny of its current valuation.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-lad/lithia-motors\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Lithia Motors.</a></p> <p>At a share price of $281.46, Lithia Motors has seen a 1 day share price return of 0.69%, set against a weaker 30 day share price return of 13.97% and a 1 year total shareholder return of 17.7%. Together, these figures point to fading momentum after earlier gains over three years.</p> <p>If this pullback has you thinking about where else capital could work harder, it might be a good time to broaden your search with our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a>.</p> <p>With Lithia trading at $281.46, an indicated 58.71% discount to one intrinsic value estimate and a 39.81% discount to the average analyst target of $393.50, you have to ask: is this a genuine opportunity, or is the market already factoring in future growth?</p> <h2>Most Popular Narrative: 28.7% Undervalued</h2> <p>On the most followed narrative, Lithia Motors' fair value of $394.57 sits well above the current $281.46 share price, which puts a lot of focus on what is driving that gap.</p> <blockquote> <p><em>Ongoing technology investments, especially the full rollout of Pinewood.AI, are expected to materially lower SG&amp;A through automation, unified workflows, and improved productivity, driving operating leverage that should improve net margins and efficiency ratios over the next several years.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/g0g50k5y-analysts-lift-lithia-motors-price-target-as-buybacks-and-expansions-drive-improved-margins\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>If you want to see what is really baked into that valuation, the core of this narrative is a specific mix of revenue growth, margin uplift, and future earnings multiples that are anything but conservative.</p> <p><strong>Result: Fair Value of $394.57 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/g0g50k5y-analysts-lift-lithia-motors-price-target-as-buybacks-and-expansions-drive-improved-margins\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, you also have to keep an eye on risks such as elevated acquisition costs or weaker organic store performance, which could challenge those margin and earnings assumptions.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-lad/lithia-motors\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Lithia Motors narrative.</a></p> <h2>Next Steps</h2> <p>With both risks and rewards on the table, what matters most is how you weigh them for your own portfolio. Take a closer look at the full picture and let the data guide your stance through <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-lad/lithia-motors\" rel=\"noopener noreferrer\" target=\"_blank\">5 key rewards and 1 important warning sign</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Lithia has sparked new questions about where your money works hardest, do not stop here. Let the screener surface fresh angles you might be missing.</p> <ul> <li>Target potential value opportunities by scanning companies on our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 high quality undervalued stocks</a> and see which ones match your return expectations and risk comfort.</li> <li>Prioritise stability by reviewing companies highlighted in the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">80 resilient stocks with low risk scores</a>, so you can focus on businesses with lower overall risk scores.</li> <li>Hunt for lesser known prospects through our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> and spot companies that may not yet be widely followed.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 00:35:55",
            "link": "https://simplywall.st/stocks/us/retail/nyse-lad/lithia-motors/news/assessing-lithia-motors-lad-valuation-after-recent-share-pri-1",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Iovance Biotherapeutics (IOVA) Attractive After Recent 33% Weekly Share Price Jump",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether Iovance Biotherapeutics at around US$3.79 is a bargain or a value trap, you are not alone. This article will walk through what the current price could mean for you.</li> <li>The stock has recently moved sharply, with a 33% return over the last 7 days, 27.2% over the last 30 days, and 50.4% year to date, even though the 1 year, 3 year and 5 year returns remain negative.</li> <li>These swings have come as investors react to ongoing developments around Iovance Biotherapeutics and its pipeline, which can quickly change sentiment around early stage biotech names. Understanding what is already baked into the share price matters if you are trying to work out whether recent moves reflect lasting shifts in expectations or short term trading.</li> <li>On our valuation checks the company scores <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">4 out of 6</a> for being undervalued. Next we will look at how different valuation approaches line up on Iovance Biotherapeutics, and then finish with a way to put those numbers into a fuller investment story.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_industry_underperformer\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/future\" rel=\"noopener noreferrer\" target=\"_blank\">Find out why Iovance Biotherapeutics's -27.9% return over the last year is lagging behind its peers.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Approach 1: Iovance Biotherapeutics Discounted Cash Flow (DCF) Analysis</h2> <p>A Discounted Cash Flow, or DCF, model takes estimates of a company‚Äôs future cash flows and discounts them back to today to arrive at an estimate of what the business could be worth right now.</p> <p>For Iovance Biotherapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in US$. The latest twelve month free cash flow is a loss of about $343.7 million. Analysts provide forecasts out to 2030, with free cash flow projections moving from a loss of $146 million in 2026 and $13 million in 2027, to positive cash flows of $143 million in 2028, $231 million in 2029 and $313 million in 2030. Beyond the analyst horizon, Simply Wall St extrapolates further free cash flow estimates out to 2035 using its own growth assumptions.</p> <p>When all of those projected cash flows are discounted back to today, the DCF model arrives at an estimated intrinsic value of about $23.63 per share. Compared with the recent share price around $3.79, this implies the stock is about 84.0% undervalued on this measure.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Iovance Biotherapeutics is undervalued by 84.0%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"IOVA Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>IOVA Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Iovance Biotherapeutics.</a></p> <h2>Approach 2: Iovance Biotherapeutics Price vs Sales</h2> <p>For companies that are not yet profitable, the P/S ratio is often more useful than P/E because it compares what investors are paying to the revenue being generated, rather than to earnings that are still negative.</p> <p>In general, higher expected growth and lower perceived risk can support a higher P/S ratio. Slower growth or higher risk tends to justify a lower one. That is why it helps to look at Iovance Biotherapeutics in the context of both its industry and its own fundamentals.</p> <p>Iovance Biotherapeutics currently trades on a P/S of 5.93x. This sits below the Biotechs industry average of 12.58x and also below the peer average of 6.82x provided. Simply Wall St‚Äôs Fair Ratio for the company is 4.19x, which is an estimate of the P/S multiple that might be reasonable given factors such as earnings growth, profit margins, industry, market cap and specific risks. Compared with simple peer or industry comparisons, the Fair Ratio aims to be more tailored to the company‚Äôs profile.</p> <p>Putting that together, Iovance Biotherapeutics‚Äô actual P/S of 5.93x is above the Fair Ratio of 4.19x, which points to the shares pricing in a richer multiple than this framework suggests.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:IOVA P/S Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/ps-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGM:IOVA P/S Ratio as at Feb 2026</figcaption></figure> <p>P/S ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Iovance Biotherapeutics Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your story about Iovance Biotherapeutics tied directly to numbers like future revenue, earnings, margins and a fair value estimate.</p> <p>On Simply Wall St‚Äôs Community page, millions of investors use Narratives as an accessible tool to connect a company‚Äôs story to a financial forecast and then to a fair value. This allows you to compare that fair value with the current share price to help decide if the stock looks attractive or stretched on your assumptions.</p> <p>Because Narratives update automatically when new information such as company announcements, earnings or analyst revisions appear, you are not locked into a static view. You can quickly see how fresh data shifts the fair value output linked to your story.</p> <p>For Iovance Biotherapeutics, one investor might build a cautious Narrative anchored around a US$1.00 fair value while another might build an optimistic Narrative around US$20.00. By setting out the revenue, earnings and P/E assumptions behind each, you can decide which version feels closer to your own view or adjust the inputs to create something in between.</p> <p>For Iovance Biotherapeutics, we will make it easy for you with previews of two leading Iovance Biotherapeutics Narratives:</p> <p><a href=\"/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/13svd0s7-amtagvi-and-new-til-will-meet-aging-global-demand?utm_medium=finance_user&amp;utm_campaign=cta_bull_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêÇ Iovance Biotherapeutics Bull Case</strong></a></p> <p>Fair value in this bullish narrative: US$17.00 per share</p> <p>Implied discount to this fair value versus the recent US$3.79 share price: about 78% below the narrative fair value</p> <p>Revenue growth assumption in this narrative: 56.96% a year</p> <ul> <li>Assumes Amtagvi adoption, broader patient access, and efficiency gains support higher revenue and a turnaround from losses to profit over the next few years.</li> <li>Builds in a higher profit margin and a future P/E of 75.10x, which is well above the current US Biotechs industry P/E referenced earlier in the article.</li> <li>Anchors on a Fair Value of US$17.00, based on bullish analyst assumptions for revenue of US$1.0b and earnings of US$126.3m by 2028, discounted back at about 7.11%.</li> </ul> <p><a href=\"/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/jv6qnzu7-rising-interest-rates-and-dilution-will-stifle-til-progress?utm_medium=finance_user&amp;utm_campaign=cta_bear_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêª Iovance Biotherapeutics Bear Case</strong></a></p> <p>Fair value in this bearish narrative: US$2.00 per share</p> <p>Implied premium to this fair value versus the recent US$3.79 share price: about 89% above the narrative fair value</p> <p>Revenue growth assumption in this narrative: 43.28% a year</p> <ul> <li>Assumes slower commercialization, high costs, complex distribution, and pressure from drug pricing scrutiny and interest rates, with continued execution risk.</li> <li>Uses a lower profit margin of 3.20% and a future P/E of 50.65x, while still baking in material revenue growth from Amtagvi and the pipeline.</li> <li>Arrives at a Fair Value of US$2.00 per share, reflecting a cautious view that the market may be pricing in more growth and profitability than these assumptions support.</li> </ul> <p>Together, these Narratives frame the recent US$3.79 share price between a bullish fair value of US$17.00 and a bearish fair value of US$2.00. Your job is to decide which story, or something in between, best fits your own expectations for Iovance Biotherapeutics.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a></p> <p>Do you think there's more to the story for Iovance Biotherapeutics? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqGM/IOVA\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:IOVA 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGM:IOVA 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 00:35:54",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/is-iovance-biotherapeutics-iova-attractive-after-recent-33-w",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "United Therapeutics Tresmi Launch And Xenotransplant Progress Shape Valuation Story",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>United Therapeutics (NasdaqGS:UTHR) has introduced Tresmi, a new soft mist inhaler platform aimed at reducing treatment side effects, including coughing.</li> <li>The company reported record annual revenue alongside this product launch.</li> <li>United Therapeutics also reported tangible progress in its organ manufacturing program focused on xenotransplantation.</li> </ul> <p>For investors watching United Therapeutics at a share price of $503.6, these updates add fresh detail to the story behind NasdaqGS:UTHR. The stock is up 4.8% over the past week and 55.6% over the past year, with a very large 3-year gain and a 214.1% return over 5 years. In that context, the combination of a new inhaler platform, record revenue, and organ manufacturing progress provides more detail on recent share price strength.</p> <p>Looking ahead, Tresmi may influence how the company positions its inhaled therapies, particularly if reduced coughing is associated with better patient adherence. Progress in xenotransplantation research may also inform how investors view the company‚Äôs long-term pipeline and potential new revenue streams. Together, these developments may be important for how the market values future opportunities at United Therapeutics.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">United Therapeutics</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NasdaqGS/UTHR\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on United Therapeutics.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:UTHR Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/f0981ea6-8c55-4492-9a4c-3acc364f2deb/chart/earnings-and-revenue-growth?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGS:UTHR Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 0 risks for United Therapeutics. See which could impact your investment.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚öñÔ∏è Price vs Analyst Target</strong>: At US$503.6 versus a US$565.08 consensus target, the price sits about 11% below analyst expectations, which indicates potential upside in the current analyst view.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: Simply Wall St currently sees United Therapeutics trading about 68.1% below its estimated fair value.</li> <li><strong>‚úÖ Recent Momentum</strong>: The 30 day return of roughly 5.6% reflects positive short term momentum as the market absorbs the Tresmi launch and organ manufacturing update.</li> </ul> <p>The decision to buy, sell or hold United Therapeutics depends on your own analysis. For more detail, see Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest assessment of United Therapeutics's fair value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä Tresmi and progress in xenotransplantation add another layer to the story alongside record revenue and existing pulmonary hypertension therapies.</li> <li>üìä It may be useful to monitor adoption of the new inhaler, any reported impact on side effects, and updates on organ manufacturing milestones or regulatory steps.</li> <li>‚ö†Ô∏è Execution risk around commercial uptake of Tresmi and the scientific, regulatory and cost hurdles in xenotransplantation could influence how quickly these projects affect results.</li> </ul> <h3>Dig Deeper</h3> <p>For a fuller picture, including additional risks and potential rewards, see the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics\" rel=\"noopener noreferrer\" target=\"_blank\">complete United Therapeutics analysis</a>. You can also visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NasdaqGS/UTHR\" rel=\"noopener noreferrer\" target=\"_blank\">community page for United Therapeutics</a> to see how other investors view the latest developments and their impact on the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 00:31:02",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/united-therapeutics-tresmi-launch-and-xenotransplant-progres",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Sysmex (TSE:6869) Now Fairly Priced After A 45% One Year Share Price Slide?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether Sysmex shares are now priced attractively or still have further to fall, this article walks through what the current share price might be implying about the company's value.</li> <li>The stock last closed at ¬•1,467, after a 9.6% move over the past 7 days, a modest 0.3% return over 30 days, and longer term returns of a 4.4% decline year to date, a 44.9% decline over 1 year, a 45.0% decline over 3 years, and a 58.1% decline over 5 years.</li> <li>Recent coverage around Sysmex has focused on its position in the healthcare sector and how investors are reassessing companies in this space, especially those with established products and global reach. This backdrop helps frame why the share price has shifted recently and why some investors are rechecking their assumptions about what a fair price looks like today.</li> <li>On our valuation checks, Sysmex currently scores <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/jp/healthcare/tse-6869/sysmex-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">3 out of 6</a>, meaning it screens as undervalued on half of the metrics we track. Next, we will look at what different valuation methods say about that score, before finishing with a more complete way to think about value that ties all of these pieces together.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_industry_underperformer\" href=\"https://www.simplywall.st/stocks/jp/healthcare/tse-6869/sysmex-shares/future\" rel=\"noopener noreferrer\" target=\"_blank\">Find out why Sysmex's -44.9% return over the last year is lagging behind its peers.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: Sysmex Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow, or DCF, model takes estimates of the cash a company may generate in future years and discounts those amounts back into today‚Äôs money to arrive at an estimated intrinsic value per share.</p> <p>For Sysmex, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in ¬•. The latest twelve month free cash flow is ¬•27,423.60 million. Analyst estimates and subsequent extrapolations point to projected free cash flow of ¬•50,425.75 million by the year ending March 2030, with a series of annual projections between now and 2035 that Simply Wall St has discounted back to today.</p> <p>When all of those projected cash flows are added and discounted, the model arrives at an estimated fair value of ¬•1,567.57 per share. Compared with the recent market price of ¬•1,467, the DCF output implies Sysmex trades at about a 6.4% discount to this estimate, which places it in the ‚Äúroughly in line‚Äù bucket rather than looking extremely cheap or expensive.</p> <p><strong>Result: ABOUT RIGHT</strong></p> <p>Sysmex is fairly valued according to our <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_fairly_valued\" href=\"https://www.simplywall.st/stocks/jp/healthcare/tse-6869/sysmex-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Discounted Cash Flow (DCF)</a>, but this can change at a moment's notice. Track the value in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_fairly_valued\" href=\"https://www.simplywall.st/watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_fairly_valued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted on when to act.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/healthcare/tse-6869/sysmex-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"6869 Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/4bfd7ddf-83f1-49f8-bedf-8070df38967e/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>6869 Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/jp/healthcare/tse-6869/sysmex-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Sysmex.</a></p> <h3>Approach 2: Sysmex Price vs Earnings</h3> <p>P/E is a useful way to think about valuation for profitable companies because it directly links what you pay for each share to the earnings that support that share. When investors expect stronger growth or see lower risk, they are usually willing to accept a higher P/E, while slower growth or higher risk tends to justify a lower P/E.</p> <p>Sysmex currently trades on a P/E of 20.4x. That is close to the Medical Equipment industry average of 15.5x and very similar to the peer average of 20.5x, so on simple comparisons the stock looks roughly in line with similar names rather than clearly cheap or expensive.</p> <p>Simply Wall St‚Äôs Fair Ratio is a proprietary estimate of what P/E might make sense for Sysmex given its earnings growth profile, industry, profit margins, market cap and risk factors. This is more tailored than a straight peer or industry comparison because those benchmarks do not adjust for company specific strengths or weaknesses. For Sysmex, the Fair Ratio is 26.6x, which is higher than the current 20.4x P/E, suggesting the shares trade below this estimate of fair value.</p> <p><strong>Result: UNDERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/healthcare/tse-6869/sysmex-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSE:6869 P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/4bfd7ddf-83f1-49f8-bedf-8070df38967e/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>TSE:6869 P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/jp\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 12 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Sysmex Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way to attach your own story about Sysmex to the numbers behind its fair value, revenue, earnings and margins.</p> <p>A Narrative is your view of what the company is doing, where it might be heading and how that could show up in future financials, all pulled together into one clear forecast and an implied fair value per share.</p> <p>On Simply Wall St, Narratives live in the Community page, where millions of investors can create and share these story driven forecasts, then compare their Fair Value to the current share price to help them decide how Sysmex fits into their portfolio.</p> <p>Because Narratives are refreshed when new information arrives, such as earnings updates or news, your fair value view can shift automatically. You will often see very different takes on Sysmex. For example, one Narrative might assume a much higher fair value than today‚Äôs price, while another assumes a much lower one, reflecting different expectations for its future.</p> <p>Do you think there's more to the story for Sysmex? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/TSE/6869\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/healthcare/tse-6869/sysmex-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSE:6869 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/4bfd7ddf-83f1-49f8-bedf-8070df38967e/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>TSE:6869 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:31:02",
            "link": "https://simplywall.st/stocks/jp/healthcare/tse-6869/sysmex-shares/news/is-sysmex-tse6869-now-fairly-priced-after-a-45-one-year-shar",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Excellon Resources (TSXV:EXN) Valuation After The New Mallay Mineral Resource Estimate",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Excellon Resources (TSXV:EXN) has put the Mallay silver lead zinc mine in Peru back in focus after releasing its first independent Mineral Resource Estimate, a key input for potential restart planning.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/ca/materials/tsxv-exn/excellon-resources-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Excellon Resources.</a></p> <p>The new Mallay resource update lands after a very large 1 year total shareholder return of about 4x, supported by a 107.87% 90 day share price return. However, 5 year total shareholder return remains deeply negative, suggesting momentum has picked up more recently than over the long run.</p> <p>If this kind of mining news has your attention, it could be a good time to see what else is moving in precious metals. You can explore our screener of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_silver\" href=\"https://simplywall.st/discover/investing-ideas/473743/top-silver-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">7 top silver producer stocks</a>.</p> <p>With the Mallay resource now on the table and the share price up sharply over the past year, the key question is whether Excellon is still trading at a discount or whether the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 97.9% Undervalued</h2> <p>According to the most followed narrative, Excellon Resources‚Äô fair value sits at CA$31.80 per share versus a last close of CA$0.66. This implies a very large gap between price and narrative value.</p> <blockquote> <p><em>Excellon has strong hands backing it, Glencore and Eric Sprott for example, and Glencore has an agreement to take all lead-zinc into 2027. Glencore is also assisting with the re-start of the Mallay mine and were partners with the former operators.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/hea33f2u-update-for-excellon-resources\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>If you want to understand why this narrative assigns such a high fair value, you need to see how the projected mine restarts, production volumes and metals pricing all fit together. The entire story hinges on how those assumptions feed into long term cash flows and what kind of valuation multiple that supports.</p> <p><strong>Result: Fair Value of CA$31.80 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_user_generated_narrative\" href=\"https://www.simplywall.st/narratives/hea33f2u-update-for-excellon-resources\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this hinges on ambitious assumptions, and any setback at Mallay or a weaker than expected metals price backdrop could quickly challenge such an optimistic fair value.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/ca/materials/tsxv-exn/excellon-resources-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Excellon Resources narrative.</a></p> <h2>Next Steps</h2> <p>With such a wide range of views on value and risk, it makes sense to look at the numbers yourself and decide where you stand. If you want a balanced snapshot of both sides, take a moment to review the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/ca/materials/tsxv-exn/excellon-resources-shares\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 4 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If this story has you thinking harder about where your money is working, do not stop here. The next idea you skip could be the one that matters.</p> <ul> <li>Target potential mispricings across the market by scanning our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/ca\" rel=\"noopener noreferrer\" target=\"_blank\">8 high quality undervalued stocks</a> built from detailed fundamental checks.</li> <li>Strengthen the defensive side of your portfolio by focusing on companies flagged in our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/ca\" rel=\"noopener noreferrer\" target=\"_blank\">7 resilient stocks with low risk scores</a>, where business quality is central.</li> <li>Hunt for lesser known opportunities by reviewing the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/ca\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 6 high quality undiscovered gems</a> that surface on our screener before they hit the mainstream.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Excellon Resources might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/ca/materials/tsxv-exn/excellon-resources-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 00:31:02",
            "link": "https://simplywall.st/stocks/ca/materials/tsxv-exn/excellon-resources-shares/news/a-look-at-excellon-resources-tsxvexn-valuation-after-the-new",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Innodata (INOD) Pricing AI Hopes Too High After Recent Share Price Swings",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>This article is designed to help you assess whether Innodata's share price aligns with its underlying worth, or if sentiment has run ahead of fundamentals.</li> <li>Innodata last closed at US$47.58, with a 4.3% return over the past week, an 18.9% decline over the past month, a 10.2% decline year to date, a 9.6% decline over 1 year and a very large 3 year and 5 year return that is more than 7x.</li> <li>Recent headlines around Innodata have focused on its role in data engineering and AI related services, including coverage of how the company positions its offerings within wider AI workflows for enterprise customers. This context helps explain why the share price has seen sharp moves as investors react to changing expectations for AI related spending and contract activity.</li> <li>Right now Innodata has a valuation score of <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/commercial-services/nasdaq-inod/innodata/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">1 out of 6 checks</a>, so we will look at what that means across different valuation methods, and then finish by considering a broader way to think about value that goes beyond any single score or model.</li> </ul> <p>Innodata scores just 1/6 on our valuation checks. See what other red flags we found in the <a class=\"company-report-links\" data-vars-link-type=\"cta_low_value_score\" href=\"https://www.simplywall.st/stocks/us/commercial-services/nasdaq-inod/innodata/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">full valuation breakdown</a>.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: Innodata Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow model takes expected future cash flows and discounts them back to today, aiming to estimate what the whole business might be worth in present value terms.</p> <p>For Innodata, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $39.24 million. Looking ahead, analysts have Innodata generating free cash flow of $27.35 million in 2026, with further annual projections out to 2035 extrapolated from those inputs by Simply Wall St rather than based on direct analyst estimates.</p> <p>When all those projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $12.53 per share. Compared with the recent share price of US$47.58, this implies the stock is 279.8% above the DCF estimate, which indicates the market is placing a much higher value on Innodata than this cash flow based approach.</p> <p><strong>Result: OVERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Innodata may be overvalued by 279.8%. <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_overvalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">Discover 54 high quality undervalued stocks</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_overvalued\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">create your own screener</a> to find better value opportunities.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/commercial-services/nasdaq-inod/innodata/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"INOD Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/41bf15e3-3242-4c6d-9919-b776429a1740/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>INOD Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/commercial-services/nasdaq-inod/innodata/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Innodata.</a></p> <h3>Approach 2: Innodata Price vs Earnings</h3> <p>For profitable companies, the P/E ratio is a useful shorthand for how much investors are currently paying for each dollar of earnings. It ties directly to the bottom line, which is ultimately what supports a share price over time.</p> <p>What counts as a ‚Äúnormal‚Äù P/E often reflects how the market views a company‚Äôs growth potential and risk. Higher expected growth or lower perceived risk can support a higher P/E, while lower growth or higher risk usually point to a lower P/E.</p> <p>Innodata currently trades on a P/E of about 45.1x. That is above the Professional Services industry average of roughly 20.6x and also above the peer average of about 21.8x, so on simple comparisons the stock carries a premium.</p> <p>Simply Wall St‚Äôs Fair Ratio for Innodata is 27.2x. This proprietary metric is designed to estimate a P/E that fits the company‚Äôs own profile, including its earnings growth, industry, profit margins, market cap and specific risks. Because it is tailored to the company, it can be more informative than just lining it up against broad industry or peer averages.</p> <p>Comparing the Fair Ratio of 27.2x with the actual P/E of 45.1x suggests the shares are pricing in more optimism than the model implies.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/commercial-services/nasdaq-inod/innodata/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:INOD P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/41bf15e3-3242-4c6d-9919-b776429a1740/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGM:INOD P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Innodata Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St you can use Narratives, where you set out your story about Innodata, link that story to explicit forecasts for revenue, earnings and margins, and the platform turns it into a Fair Value that you can compare with the current price on the Community page used by millions of investors. Each Narrative updates automatically when new news or earnings land, so you can quickly see how a more optimistic view, such as a Fair Value around US$110.00, stacks up against a more cautious view closer to US$80.00. You can then decide for yourself whether Innodata looks closer to a buy, a hold or a sell for your own approach.</p> <p>Do you think there's more to the story for Innodata? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqGM/INOD\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/commercial-services/nasdaq-inod/innodata\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:INOD 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/41bf15e3-3242-4c6d-9919-b776429a1740/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGM:INOD 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 00:31:02",
            "link": "https://simplywall.st/stocks/us/commercial-services/nasdaq-inod/innodata/news/is-innodata-inod-pricing-ai-hopes-too-high-after-recent-shar",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is First Financial Bankshares (FFIN) Price Justified After Recent Rebound And Sector Concerns",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether First Financial Bankshares is reasonably priced or you might be overpaying at US$33.45, you are asking the right question before making any decisions.</li> <li>The share price has moved 1.1% over the last week, 5.1% over the past month, and 11.4% year to date, while the 1 year return sits at an 8.2% decline and the 3 and 5 year returns are 0.5% and 18.0% declines respectively.</li> <li>Recent coverage has focused on broad sector trends and regional bank conditions, which helps frame how investors think about the risk and reward trade off for smaller lenders like First Financial Bankshares. This context is important when you look at a share price that has shorter term gains alongside weaker multi year returns.</li> <li>On our checks, First Financial Bankshares has a valuation score of <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/banks/nasdaq-ffin/first-financial-bankshares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">2 out of 6</a>. Next we will walk through the usual P/E, P/B and cash flow based approaches, then finish with a more rounded way to think about value beyond a single score.</li> </ul> <p>First Financial Bankshares scores just 2/6 on our valuation checks. See what other red flags we found in the <a class=\"company-report-links\" data-vars-link-type=\"cta_low_value_score\" href=\"https://www.simplywall.st/stocks/us/banks/nasdaq-ffin/first-financial-bankshares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">full valuation breakdown</a>.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Approach 1: First Financial Bankshares Excess Returns Analysis</h2> <p>The Excess Returns model looks at how much profit a company can earn above its cost of equity and then capitalizes those surplus returns into an estimated fair value per share.</p> <p>For First Financial Bankshares, the model starts with a Book Value of $13.48 per share and a Stable EPS of $2.13 per share, based on weighted future Return on Equity estimates from 5 analysts. The Average Return on Equity used is 13.75%, against a Cost of Equity of $1.08 per share. The difference between what the bank is expected to earn and what investors require, the Excess Return, is $1.05 per share.</p> <p>The Stable Book Value is set at $15.51 per share, using weighted future Book Value estimates from 4 analysts. These inputs are combined in the Excess Returns framework to arrive at an intrinsic value estimate of about $44.95 per share.</p> <p>Comparing this to the current share price of $33.45 indicates the stock is about 25.6% undervalued according to this model.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Excess Returns analysis suggests First Financial Bankshares is undervalued by 25.6%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/banks/nasdaq-ffin/first-financial-bankshares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"FFIN Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/71abcb0a-2e44-4d27-a548-476c3e10f599/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>FFIN Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/banks/nasdaq-ffin/first-financial-bankshares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for First Financial Bankshares.</a></p> <h2>Approach 2: First Financial Bankshares Price vs Earnings</h2> <p>For a profitable company like First Financial Bankshares, the P/E ratio is a straightforward way to think about what you are paying for each dollar of current earnings. It is widely used because it links directly to the earnings that ultimately support dividends and retained capital.</p> <p>What counts as a ‚Äúnormal‚Äù or ‚Äúfair‚Äù P/E partly reflects how the market views a company‚Äôs growth potential and risk profile. Higher expected growth or lower perceived risk can justify a higher P/E, while slower expected growth or higher risk usually comes with a lower P/E.</p> <p>First Financial Bankshares currently trades on a P/E of 18.77x. That sits above the Banks industry average of 11.75x and the peer average of 12.98x, which on simple comparisons can make the shares look relatively expensive. Simply Wall St‚Äôs Fair Ratio framework goes a step further by estimating what P/E might be reasonable given factors like earnings growth, profit margins, industry, market cap and specific risks. For First Financial Bankshares, the Fair Ratio is 12.72x, which is meaningfully below the current 18.77x and suggests the shares trade richer than this model would indicate.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/banks/nasdaq-ffin/first-financial-bankshares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:FFIN P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/71abcb0a-2e44-4d27-a548-476c3e10f599/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGS:FFIN P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your First Financial Bankshares Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your story about a company linked directly to your assumptions for fair value, future revenue, earnings and margins. On Simply Wall St‚Äôs Community page, used by millions of investors, you can set up a Narrative for First Financial Bankshares that connects what you believe about its business to a financial forecast and a fair value, then compare that fair value to the current price to help you decide whether it looks attractive or not right now. Narratives are easy to adjust and are updated when new information like news or earnings arrives, so your view does not stay stuck on old data. For example, one investor might see First Financial Bankshares as worth well above today‚Äôs price while another might see it as worth well below, and those different fair values sit side by side on the platform so you can judge which story you find more convincing.</p> <p>Do you think there's more to the story for First Financial Bankshares? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqGS/FFIN\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/banks/nasdaq-ffin/first-financial-bankshares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:FFIN 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/71abcb0a-2e44-4d27-a548-476c3e10f599/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGS:FFIN 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 00:31:01",
            "link": "https://simplywall.st/stocks/us/banks/nasdaq-ffin/first-financial-bankshares/news/is-first-financial-bankshares-ffin-price-justified-after-rec",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "MercadoLibre (MELI) Margin Compression To 6.9% Tests Bullish Profitability Narratives",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>MercadoLibre FY 2025 earnings snapshot</h2> <p>MercadoLibre (MELI) has wrapped up FY 2025 with fourth quarter revenue of US$8.8b and basic EPS of US$11.03, alongside net income of US$559m, putting fresh numbers behind the recent share price of US$1,740.88. The company has seen quarterly revenue move from US$6.1b and EPS of US$12.60 in Q4 2024 to US$8.8b and EPS of US$11.03 in Q4 2025, while trailing twelve month EPS sits at US$39.39 on revenue of US$28.9b. This gives investors a basis to weigh high forecast growth against softer profit margins. Overall, the release gives a clear picture of a business adding scale, while margins leave more room for debate.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/us/retail/nasdaq-meli/mercadolibre\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for MercadoLibre.</a> <p>With the headline numbers on the table, the next step is to see how this mix of strong top line scale and pressured margins lines up with the stories investors usually tell about MercadoLibre and where those narratives might need an update.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_range_narrative\" href=\"https://www.simplywall.st/narratives/8n0hbqk4-the-fintech-eclipse-when-the-bank-eats-the-store\" rel=\"noopener noreferrer\" target=\"_blank\">See what the community is saying about MercadoLibre</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/retail/nasdaq-meli/mercadolibre/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:MELI Earnings &amp; Revenue History as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/900c4fca-b361-4353-b833-3ef19f581a4b/chart/earnings-and-revenue-history?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGS:MELI Earnings &amp; Revenue History as at Feb 2026</figcaption></figure> <h2>P/E of 44.2x with TTM EPS of US$39.39</h2> <ul> <li>With trailing twelve month EPS at US$39.39 and a share price of US$1,740.88, MercadoLibre is trading on a P/E of 44.2x, compared with a peer average of 38x and a broader industry figure of 18.1x.</li> <li>Consensus narrative notes that analysts expect earnings to grow about 23.5% per year while revenue is expected to grow around 17.1% per year, and\n    <ul> <li>those growth expectations sit next to a single year trailing earnings growth of 4.5%, which is far below the 55.2% per year average over five years,</li> <li>so the current 44.2x multiple asks investors to weigh a higher near term valuation against the idea that earnings growth could move closer to analyst forecasts again.</li> </ul> </li> </ul> <p>Consistent earnings growth expectations and a premium P/E often split opinions. If you want to see how other investors are framing this, it can help to read the broader community take on MELI. <a class=\"company-report-links\" data-vars-link-type=\"cta_consensus_narrative_link\" href=\"https://simplywall.st/stock/NasdaqGS/MELI\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üìä Read the what the Community is saying about MercadoLibre.</strong></a></p> <h2>Revenue expanding while net margin slips to 6.9%</h2> <ul> <li>On a trailing twelve month basis, revenue is US$28.9b with net income of US$2.0b, which works out to a 6.9% net margin compared with 9.2% in the prior year dataset.</li> <li>Bulls highlight ecosystem benefits across commerce, fintech and logistics as a support for margin potential, and\n    <ul> <li>point to areas like logistics and product expansion as possible long term sources of operating leverage, while the current 6.9% margin shows profits have not matched the pace of revenue scale yet,</li> <li>so the bullish view that margin expansion can continue over time has to be weighed against the recent margin compression visible in the trailing numbers.</li> </ul> </li> </ul> <p>Supporters of the growth story often focus on how the business model could translate this revenue base into higher margins over time, and you can see how they connect these latest figures to their longer term view in the dedicated bull case for MercadoLibre. <a class=\"company-report-links\" data-vars-link-type=\"cta_bull_narrative_link\" href=\"https://simplywall.st/narratives/t648uy1z-digital-mobile-and-fintech-trends-will-fuel-latin-american-ecosystems\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêÇ MercadoLibre Bull Case</strong></a></p> <h2>DCF fair value above price, but debt flagged as high</h2> <ul> <li>The shares trade at US$1,740.88 against a DCF fair value of about US$2,248.80 and an analyst price target of US$2,731.42, while the same dataset flags a high level of debt and a net margin of 6.9%.</li> <li>Bears argue that competition, high spending and leverage could make it harder for MercadoLibre to convert growth into higher net income, and\n    <ul> <li>the combination of a premium 44.2x P/E and a lower trailing margin than the prior year is consistent with that concern that profitability could face pressure,</li> <li>so even though DCF fair value and analyst targets sit above the current price, the flagged high debt level gives cautious investors a concrete balance sheet risk to keep in mind.</li> </ul> </li> </ul> <p>Investors who focus on the risk side often drill into debt, competition and margins, and you can see that argument laid out in more detail in the dedicated bear case for MercadoLibre. <a class=\"company-report-links\" data-vars-link-type=\"cta_bear_narrative_link\" href=\"https://simplywall.st/narratives/oxjcqqpz-fierce-stripe-and-paypal-competition-will-weaken-latin-america-prospects\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêª MercadoLibre Bear Case</strong></a></p> <h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://www.simplywall.st/narratives/8n0hbqk4-the-fintech-eclipse-when-the-bank-eats-the-store\" rel=\"noopener noreferrer\" target=\"_blank\">community narratives</a> for MercadoLibre on Simply Wall St. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> so you'll be alerted when the story evolves.</p> <p>The mix of upbeat and cautious signals in this article might raise questions, and that is exactly the point. Now is a good time to examine the full picture yourself and weigh both sides through <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/retail/nasdaq-meli/mercadolibre\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 2 important warning signs</a>.</p> <h2>See What Else Is Out There</h2> <p>MercadoLibre is growing its revenue base, but the slip in net margin to 6.9% and the premium 44.2x P/E highlight profitability and balance sheet concerns.</p> <p>If those margin pressures and debt flags make you cautious, it is worth checking companies on our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/us\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (41 results)</a> that aim for sturdier financial footing right now.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 00:26:00",
            "link": "https://simplywall.st/stocks/us/retail/nasdaq-meli/mercadolibre/news/mercadolibre-meli-margin-compression-to-69-tests-bullish-pro",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Hysan Development (SEHK:14) First Half EPS Recovery Tests Bullish Margin Narratives",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Hysan Development (SEHK:14) has put fresh numbers on the table for FY 2025, with first half revenue at HK$1,838 million and basic EPS of HK$0.07. This sets the tone after a mixed FY 2024 that saw revenue move from HK$1,613 million to HK$1,713 million, while EPS shifted between HK$0.42 and a loss of HK$0.38. Over the trailing 12 months, revenue ranged between HK$3,326 million and HK$3,551 million, with EPS moving from HK$0.03 to HK$0.31. This gives investors a broader view of how earnings power has been resetting. With margins now framed by a higher reported net margin and a large one off loss in the background, the latest print puts the focus firmly on how durable that profitability profile really is.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/hk/real-estate-management-and-development/hkg-14/hysan-development-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for Hysan Development.</a> <p>With the headline figures on the table, the next step is to see how these results line up against the key narratives around growth, risk, and income that have been shaping expectations for Hysan Development.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_range_narrative\" href=\"https://www.simplywall.st/narratives/mz19jazy-14-consistent-outlook-will-sustain-momentum-amid-stability-in-core-metrics\" rel=\"noopener noreferrer\" target=\"_blank\">See what the community is saying about Hysan Development</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/hk/real-estate-management-and-development/hkg-14/hysan-development-shares/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"SEHK:14 Revenue &amp; Expenses Breakdown as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/a012acf1-f3a5-4e13-bc90-fc88e1b130c6/chart/revenue-and-expenses-breakdown?date=2026-02-27\" width=\"746\"/></a><figcaption>SEHK:14 Revenue &amp; Expenses Breakdown as at Feb 2026</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>HK$900m one off swings margin picture</h2> <ul> <li>Trailing 12 month net income excluding extra items sits at HK$840 million on HK$3,464 million of revenue, and that comes alongside a HK$900 million one off loss that materially shaped the reported 24.2% net margin versus 1.1% last year.</li> <li>Bulls argue that projects like Lee Garden Eight and the wider Lee Gardens ecosystem can support higher recurring rental income and margins. However, the size of that HK$900 million item and the move from a loss of HK$317 million in the prior 12 months to HK$840 million now means part of the earnings jump reflects clean up effects rather than just ongoing rental strength.\n    <ul> <li>Supporters point to data driven loyalty programs and curated retail that are already linked with higher tenant sales and traffic, but these sit beside a period where basic EPS on a trailing basis moved from HK$0.03 to HK$0.31 with help from that one off adjustment.</li> <li>If you are leaning toward the bullish story, it is worth separating what comes from steady HK$3,326 million to HK$3,551 million revenue over the last few reported periods and what is tied to that HK$900 million event.</li> </ul> </li> </ul> <h2>P/E premium and 21.2% earnings growth forecast</h2> <ul> <li>At a share price of HK$21.82, the trailing P/E of 26.7x sits well above both peers at 14.2x and the wider Hong Kong real estate industry at 14.4x, while earnings are forecast to grow about 21.2% per year and revenue is forecast at 3.7% annual growth versus 8.6% for the market.</li> <li>Consensus narrative points to a business that could lift earnings meaningfully over time, but the combination of a P/E almost double peer levels and revenue growth forecasts that trail the broader market invites questions about how much of that 21.2% earnings growth is already reflected in today‚Äôs HK$21.82 price.\n    <ul> <li>Analysts are effectively assuming stronger margins can do the heavy lifting, while the DCF fair value of HK$11.15 sits well below the current price, which suggests the market is comfortable paying up based on those margin assumptions.</li> <li>If you prefer to stress test that view, you might compare the current premium multiple and DCF fair value gap with what you would expect given revenue growth that is below the 8.6% market forecast.</li> </ul> </li> </ul> On a strong earnings growth story priced at a 26.7x P/E, some investors want to see exactly how bullish analysts think this can go before they decide how to weigh that premium. <a class=\"company-report-links\" data-vars-link-type=\"cta_bull_narrative_link\" href=\"https://simplywall.st/narratives/1c6fv52l-update-for-hysan-development\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêÇ Hysan Development Bull Case</strong></a> <h2>Debt coverage and dividend pressure</h2> <ul> <li>The company offers a 4.95% dividend yield, yet dividends are flagged as not well covered by earnings and debt is described as not well covered by operating cash flow, which makes the balance sheet a key watchpoint alongside the income stream.</li> <li>Bears highlight that weaker debt coverage and reliance on instruments like perpetual securities can leave less headroom if rental conditions stay tough, and the data here backs their focus because cash flow coverage of debt and dividend payout are both identified as pressure points rather than strengths.\n    <ul> <li>Critics also note that while trailing margins look strong at 24.2%, that sits beside concerns about refinancing costs and the need to keep funding projects like Lee Garden Eight and other developments.</li> <li>If you are weighing the cautious view, the combination of a near 5% yield, limited earnings cover, and flagged debt coverage risk gives you a clear list of financial items to track in the next few reporting periods.</li> </ul> </li> </ul> When dividends are not well covered and debt coverage is marked out as a risk, some investors prefer to walk through the cautious case in detail before committing fresh capital. <a class=\"company-report-links\" data-vars-link-type=\"cta_bear_narrative_link\" href=\"https://simplywall.st/narratives/40zdes1c-update-for-hysan-development\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêª Hysan Development Bear Case</strong></a> <h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://www.simplywall.st/narratives/mz19jazy-14-consistent-outlook-will-sustain-momentum-amid-stability-in-core-metrics\" rel=\"noopener noreferrer\" target=\"_blank\">community narratives</a> for Hysan Development on Simply Wall St. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> so you'll be alerted when the story evolves.</p> <p>Reading through this, you can probably sense both enthusiasm and caution in the story. Consider reviewing the full picture for yourself, including <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/hk/real-estate-management-and-development/hkg-14/hysan-development-shares\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 3 important warning signs</a>.</p> <h2>See What Else Is Out There</h2> <p>Hysan Development carries a relatively high P/E, relies on a large one off item to support margins, and faces pressure around dividend cover and debt.</p> <p>If those balance sheet and payout pressures are giving you pause, you might want to compare them with companies screened for stronger debt cover and income resilience through our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/global\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (372 results)</a>.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Hysan Development might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/hk/real-estate-management-and-development/hkg-14/hysan-development-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 00:26:00",
            "link": "https://simplywall.st/stocks/hk/real-estate-management-and-development/hkg-14/hysan-development-shares/news/hysan-development-sehk14-first-half-eps-recovery-tests-bulli",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Constellation Energy (CEG) Is Up 10.9% After Expanded Data Center Power Deals And Dividend Update ‚Äì Has The Bull Case Changed?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In February 2026, Constellation Energy reported fourth-quarter and full-year 2025 results showing higher sales but lower net income year over year, while also closing its Calpine acquisition, announcing a quarterly dividend of US$0.4265 per share, and expanding long-term data center power agreements including a 380 MW deal with CyrusOne in Texas.</li> <li>Together, the stronger revenue, dividend increase plans, and growing roster of data center and tech customers highlight how Constellation is tying its clean-energy and gas portfolio more tightly to long-duration, AI-driven electricity demand.</li> <li>We‚Äôll now assess how the expanded data center power agreements may influence Constellation Energy‚Äôs existing investment narrative and future risk-reward balance.</li> </ul><p>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Constellation Energy Investment Narrative Recap</h2><p>To own Constellation Energy, you need to believe its enlarged clean and gas fleet can convert long-term, AI and data center driven power demand into durable cash flows, despite cyclicality in earnings and a rich valuation. The latest results, with higher sales but lower net income, do not materially change that core thesis. Near term, the key catalyst is how Calpine integration and new contracts feed into the upcoming 2026 guidance, while execution and regulatory costs on the nuclear side remain a central risk.</p> <p>The Calpine acquisition and the new 380 MW CyrusOne agreement in Texas look most relevant here, because they show how Constellation is using its broadened generation base to anchor multi-year data center deals above 1,100 MW in that state alone. Those contracts sit squarely in the middle of the current catalyst stack, but they also concentrate exposure to a handful of hyperscale buyers and grid bottlenecks in fast-growing regions.</p> <p>Yet even with this growth story, investors should be aware of how rising nuclear compliance and decommissioning costs could eventually pressure...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/utilities/nasdaq-ceg/constellation-energy/a8rpzb32-ai-power-demand-and-nuclear-momentum-will-unlock-new-opportunities-ahead\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Constellation Energy (it's free!)</a></p><p>Constellation Energy's narrative projects $26.7 billion revenue and $3.6 billion earnings by 2028. This requires 2.5% yearly revenue growth and about a $0.6 billion earnings increase from $3.0 billion today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/utilities/nasdaq-ceg/constellation-energy/a8rpzb32-ai-power-demand-and-nuclear-momentum-will-unlock-new-opportunities-ahead\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Constellation Energy's forecasts yield a $399.93 fair value</a>, a 24% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/utilities/nasdaq-ceg/constellation-energy\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"CEG 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/723936ce-ac93-41ad-9a83-ad5f056b4c40/chart/quote-price\" width=\"746\"/></a><figcaption>CEG 1-Year Stock Price Chart</figcaption></figure> <p>Some of the lowest ranked analysts were far more pessimistic, previously assuming revenue could shrink toward about US$21.6 billion and earnings to around US$1.6 billion, which contrasts sharply with the cleaner power and Calpine driven upside that others see; as you weigh this new data center news, it is worth recognising how widely views can differ and considering more than one version of the future.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/utilities/nasdaq-ceg/constellation-energy\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 13 other fair value estimates on Constellation Energy</a> - why the stock might be worth as much as 49% more than the current price!</p><h2>The Verdict Is Yours</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Constellation Energy research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/utilities/nasdaq-ceg/constellation-energy\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/utilities/nasdaq-ceg/constellation-energy\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Constellation Energy research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Constellation Energy's overall financial health at a glance.</li></ul><h2>Interested In Other Possibilities?</h2><p>The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:</p><ul><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>This technology could replace computers: discover <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 stocks that are working to make quantum computing a reality</a>.</li><li>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 00:26:00",
            "link": "https://simplywall.st/stocks/us/utilities/nasdaq-ceg/constellation-energy/news/constellation-energy-ceg-is-up-109-after-expanded-data-cente",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "What Hokkaido Electric Power Company (TSE:9509)'s Accelerated Ishikariwan Shinko Unit 2 Plan Means For Shareholders",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Hokkaido Electric Power recently increased the planned installed capacity at its Ishikariwan Shinko LNG thermal power station to about 580,000 kW and moved up the start of construction for Unit 2 from May 2027 to August 2026, reinforcing its thermal generation plans ahead of future demand needs.</li> <li>This acceleration of project timing and modest capacity uplift highlights how the utility is actively reshaping its generation mix to support supply reliability while addressing decarbonization pressures.</li> <li>Next, we‚Äôll examine how accelerating Unit 2‚Äôs construction at Ishikariwan Shinko shapes Hokkaido Electric Power‚Äôs broader investment narrative.</li> </ul><p>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>What Is Hokkaido Electric Power Company's Investment Narrative?</h2><p>To own Hokkaido Electric Power, you need to be comfortable with a regulated utility that is still reshaping its balance between reliability, capital intensity and decarbonization. Short term, the key catalysts remain earnings delivery against the updated FY2025/26 guidance, the recently increased dividends, and how the market continues to price a low P/E against modest growth forecasts. The Ishikariwan Shinko Unit 2 acceleration fits into this by modestly reinforcing the investment story around supply stability, but it also underscores the ongoing need for heavy capex in a business where debt is not well covered by operating cash flow and dividend cover looks tight. Given the already strong share price gains, this project tweak looks more incremental than transformational to the near term risk‚Äëreward.</p> However, investors should be aware of how rising capex could strain cash generation and dividends.\n\nHokkaido Electric Power Company's shares are on the way up, but they could be overextended by 35%. <a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover the fair value now</a>.<h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSE:9509 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/c387b43e-a10f-4156-b065-ce343cad1687/chart/quote-price\" width=\"746\"/></a><figcaption>TSE:9509 1-Year Stock Price Chart</figcaption></figure> The single fair value estimate from the Simply Wall St Community centers tightly around ¬•909.82 per share, contrasting with recent market pricing. When you set that against capex, balance sheet and dividend pressures discussed above, it underlines how differently participants can weigh Hokkaido Electric Power‚Äôs evolving risk profile and encourages you to consider several viewpoints before forming a view.<p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/jp/utilities/tse-9509/hokkaido-electric-power-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore another fair value estimate on Hokkaido Electric Power Company</a> - why the stock might be worth as much as ¬•910!</p><h2>The Verdict Is Yours</h2><p>Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Hokkaido Electric Power Company research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Hokkaido Electric Power Company research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hokkaido Electric Power Company's overall financial health at a glance.</li></ul><h2>Want Some Alternatives?</h2><p>Our daily scans reveal stocks with breakout potential. Don't miss this chance:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Hokkaido Electric Power Company might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 00:26:00",
            "link": "https://simplywall.st/stocks/jp/utilities/tse-9509/hokkaido-electric-power-shares/news/what-hokkaido-electric-power-company-tse9509s-accelerated-is",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "HP Q1 Beat Highlights AI PC Momentum And Memory Cost Challenge",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>HP Inc. (NYSE:HPQ) reported fiscal Q1 2026 results with Personal Systems net revenue growth and AI PCs making up more than one third of shipments.</li> <li>The company faced a sharp jump in memory costs, roughly doubling over the quarter, which pressured margins.</li> <li>Management responded with cost mitigation moves, including product redesigns, supply agreements, and selective pricing actions, while continuing to return capital to shareholders.</li> </ul> <p>For investors watching NYSE:HPQ, the latest quarter pairs operational pressure with clear traction in AI PCs. The stock trades at $18.81 and is down 15.0% year to date and 40.7% over the past year, reflecting a tough stretch despite the progress in newer product categories.</p> <p>Looking ahead, the key questions for you are how effectively HP manages elevated memory costs and whether AI PC demand remains strong enough to support margins. The company‚Äôs focus on redesigning products, adjusting pricing, and locking in supply terms will be central to how these Q1 trends develop over the coming quarters.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/tech/nyse-hpq/hp/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">HP</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/HPQ\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on HP.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/tech/nyse-hpq/hp\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:HPQ 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/e5cd5baa-f00d-431a-b8ac-e9cf16c31568/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:HPQ 1-Year Stock Price Chart</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_ownership\" href=\"https://www.simplywall.st/stocks/us/tech/nyse-hpq/hp/ownership\" rel=\"noopener noreferrer\" target=\"_blank\">See which insiders are buying and buying and selling HP following this latest news.</a></p> <p>For current and prospective shareholders, this Q1 update sends a mixed but useful signal. On one hand, HP outperformed expectations on both revenue and EPS, with net revenue of US$14.4b compared to US$13.5b a year earlier and non GAAP EPS above consensus. On the other, operating income fell and management is guiding toward the lower end of its full year earnings ranges as DRAM and NAND costs pressure margins. That combination often leads to short term share price weakness, which you are already seeing. However, it also gives you clearer information on how management plans to handle higher input costs through product re configuration, supplier diversification and selective price increases. The fact that HP maintained its fiscal 2026 GAAP EPS range of US$2.47 to US$2.77 while outlining a US$1b cost savings plan suggests management is trying to balance investment in AI PCs with disciplined capital returns, including US$0.6b returned in Q1 and continued buybacks. Against a backdrop of insider share sales and mixed institutional flows, this quarter is likely to be read as a test of whether HP can convert strong AI PC demand into durable earnings power rather than just a one off beat.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>How This Fits Into The HP Narrative</h3> <ul> <li>The strong Q1, with AI PCs at more than one third of shipments and Personal Systems growth, supports the narrative that AI driven PCs and premium devices can underpin revenue and margin resilience.</li> <li>The sharp rise in memory costs and guidance toward the low end of EPS ranges challenges the view that cost restructuring alone can fully offset input cost pressure and structural headwinds in Print.</li> <li>The specific memory cost inflation and the US$1b mitigation plan through FY2028 add more detail on cost risks and timing that are only partially reflected in the existing narrative about restructuring and supply chain diversification.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.\n<a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/narratives/9fda6tiy-ai-demand-and-margin-pressures-will-shape-performance-amid-digital-sector-shifts\" rel=\"noopener noreferrer\" target=\"_blank\"> Check out one of the top narratives in the Simply Wall St Community for HP</a> to help decide what it's worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>‚ö†Ô∏è Rising DRAM and NAND prices are creating a roughly US$0.30 full year EPS headwind, which could keep Personal Systems margins below the long term range if mitigation falls short.</li> <li>‚ö†Ô∏è Analysts and risk models highlight four key risk factors, including negative shareholders‚Äô equity and concerns around dividend stability and leverage, which may limit how aggressive HP can be with buybacks and payouts.</li> <li>üéÅ AI PCs already account for over 35% of shipments, supporting the view that HP can benefit if the PC refresh cycle and demand for higher spec devices continue to support the Personal Systems segment.</li> <li>üéÅ Management is pursuing US$1b in gross run rate savings by FY2028 and has continued to return capital through buybacks and dividends, which some investors may see as supportive of per share metrics if executed carefully.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, you may want to track three things closely. First, how quickly memory cost inflation stabilises or is offset through supplier agreements, product design changes and pricing. Second, whether AI PC growth remains strong enough to support revenue and operating margins, especially compared with peers like Dell, Lenovo and Apple in higher end PCs. Third, how capital allocation evolves, including the pace of buybacks after repurchasing 13.3m shares in the latest quarter and any shift in dividend policy, given the balance sheet risk indicators. Insider trading patterns and institutional positioning can also give you extra context on how other market participants are reacting to these moving pieces.</p> <p>To ensure you're always in the loop on how the latest news impacts the investment narrative for HP, head to the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/HPQ\" rel=\"noopener noreferrer\" target=\"_blank\"> community page for HP</a> to never miss an update on the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if HP might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/tech/nyse-hpq/hp/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 00:26:00",
            "link": "https://simplywall.st/stocks/us/tech/nyse-hpq/hp/news/hp-q1-beat-highlights-ai-pc-momentum-and-memory-cost-challen",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        }
    ]
}